Likewise, development of versatile drug carriers with a high loading capacity, such as nanoparticles, which are optimized for specific binding to cell surface receptors, and which are favoring both macropinocytic uptake and intracellular release by degradation of their shells, may open new ways for, e.g., cancer therapy. This evidence concerns the gene CD177 and cancer.